Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use. However, selection of an optimum target and payload c...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Sci Rep
المؤلفون الرئيسيون: Hoffmann, Ricarda M., Mele, Silvia, Cheung, Anthony, Larcombe-Young, Daniel, Bucaite, Gintare, Sachouli, Eirini, Zlatareva, Iva, Morad, Hassan O. J., Marlow, Rebecca, McDonnell, James M., Figini, Mariangela, Lacy, Katie E., Tutt, Andrew J. N., Spicer, James F., Thurston, David E., Karagiannis, Sophia N., Crescioli, Silvia
التنسيق: Artigo
اللغة:Inglês
منشور في: Nature Publishing Group UK 2020
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7264231/
https://ncbi.nlm.nih.gov/pubmed/32483228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-65860-x
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة